108 citations
,
April 2004 in “Medicinal Research Reviews” This review discusses the medicinal chemistry of steroid sulfatase inhibitors for estrogen- and androgen-dependent disorders but reports no new clinical results.
83 citations
,
July 2008 in “Current Opinion in Chemical Biology” This review discusses the structural and functional advances in understanding sulfotransferases and sulfatases, highlighting new insights into enzyme mechanisms and inactivation by clinically relevant aryl sulfamates, but provides no new experimental results.
25 citations
,
May 2003 in “Expert Opinion on Therapeutic Patents” This review examines patents and publications on steroid sulfatase inhibitors since 1999 and reports no new clinical results, highlighting their potential for treating estrogen- and androgen-driven conditions.
47 citations
,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” This study reports that 2-(1-Adamantyl)-4H-thiochromen-4-on-6-O-sulfamate is the most potent steroid sulfatase inhibitor identified so far, exhibiting 170-fold higher activity than the lead compound estrone sulfamate.